The impact on clinical outcome of high prevalence of diabetes mellitus in Taiwanese patients with colorectal cancer by Ching-Wen Huang et al.
Huang et al. World Journal of Surgical Oncology 2012, 10:76
WORLD JOURNAL OF 
SURGICAL ONCOLOGY 
http://www.wjso.com/content/10/1/76RESEARCH Open AccessThe impact on clinical outcome of high
prevalence of diabetes mellitus in Taiwanese
patients with colorectal cancer
Ching-Wen Huang1,2,3†, Li-Chu Sun4,5†, Ying-Ling Shih4,5, Hsiang-Lin Tsai6,7, Chao-Wen Chen8, Yung-Sung Yeh8,
Cheng-Jen Ma2, Che-Jen Huang2,9 and Jaw-Yuan Wang2,3,4,9,10,11,12*Abstract
Background: Both colorectal cancer (CRC) and diabetes mellitus (DM) are important public health problems
worldwide. As there are controversies about survival impact on CRC patients with preexisting DM, the purpose of the
present study is to evaluate the incidence and the survival impact of preexisting DM on the long-term outcomes of
patients with CRC in Taiwan.
Methods: From January 2002 to December 2008, 1,197 consecutive patients with histologically proven primary CRC, who
received surgical treatment at a single institution, were enrolled. The clinicopathologic features between these patients
with and without DM were retrospectively investigated. Moreover, we intended to analyze the impact of DM on overall
survival (OS) and cancer-specific survival (CSS) rates.
Results: Of 1,197 CRC patients, 23.6% of patients had either a reported history of DM or were currently taking one or
more diabetes-controlling medications. CRC patients with DM were significantly older than those without DM (P < 0.001),
and had a higher incidence of cardiac disease and higher body mass index than those without DM (both P< 0.001).
There were no significant differences in gender, tumor size, tumor location, histological type, AJCC/UICC cancer stage,
vascular invasion, perineural invasion, comorbidity of pulmonary disease or renal disease, and OS, and CSS between two
groups. Additionally, DM patients had a higher incidence of second malignancy than patients without DM (9.54% vs
6.01%, P=0.040).
Conclusions: A considerably high prevalence of DM in CRC patients but no significant impact of DM on survival was
observed in the single-institution retrospective study, regardless of cancer stages and tumor locations. Therefore,
treatment strategies for CRC patients with DM should be the same as patients without DM.
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Colorectal cancer (CRC) is reported as the third most com-
mon cancer and the second leading cause of cancer death
in the United States [1,2]. In the United States, an estimated
142,570 newly diagnosed cases of CRC and an estimated
51,370 cancer deaths from CRC were reported in 2010 [1].* Correspondence: cy614112@ms14.hinet.net
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reproduction in any medium, provided the orIt has been reported that the incidence of CRC in econom-
ically transitioning countries continues to rise and the inci-
dence of CRC in economically developed countries has
stabilized or is declining [3,4]. There was a 33.36% decrease
CRC-related death rate in 2006 compared with that in 1990
[1]. In Taiwan, CRC is the third leading cause of cancer-
related deaths and the death rate was 19.6 per 100,000 in
2009 [5]. Furthermore, there was a 26.45% increase in the
CRC-related death rate in 2009 compared with that in 2001
and a 59.35% increase compared with that in 1996 [5].
Diabetes mellitus (DM) is one of the most important
public problems worldwide. The International Diabetes
Federation estimates that 285 million people around theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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expected to rise to 438 million within 20 years [6]. Be-
cause a Western style diet, sedentary lifestyle and obesity
are the risk factors of DM, the prevalence and incidence
of DM have increased rapidly. The prevalence of DM is
3 to 7% in economically developed countries and 2 to
5% in economically transitioning countries [6]. In Tai-
wan, the age and gender-adjusted prevalence of DM is
6.6% for the general population; meanwhile, the preva-
lence of DM is 20.2% in populations older than 60 years
[5]. In Taiwan, DM is the fifth leading cause of death
and the death rate was 35.66 per 100,000 in 2009 [5].
DM has been shown to be associated with increased risk
of many types of cancer, including liver [7], pancreatic
[8-10], endometrial [11], colorectal [12-19], breast [20],
and bladder [21]. A Western style diet, sedentary lifestyle
and obesity are the risk factors for both DM and CRC;
consequently, many studies have shown a 24 to 60%
increased risk of developing CRC in DM patients [12-19].
Though the impact of preexisting diabetes on the out-
comes of patients with newly diagnosed CRC has been
evaluated previously, results have varied from different
countries. A significantly higher rate of overall mortality
and cancer recurrence was found in patients with DM
and high-risk stage II and stage III colon cancer [22].
Coughlin et al. reported that diabetes was significantly
associated with fatal colon cancer in men and women
[23]. Similarly, Huang et al. showed that diabetes is a
poor prognostic factor in patients with newly diagnosed
colon cancer, and it may directly impact the tumor be-
havior of stage II disease [24]. On the contrary, some
investigators demonstrated that DM did not affect the
short-term survival or the cancer specific survival [25].
There are controversies about the impact of preexisting
diabetes on the outcomes of patients with newly diag-
nosed CRC. Therefore, we conducted a retrospective
study to evaluate the survival impact of preexisting dia-




This retrospective cohort study included 1,197 consecu-
tive patients with histologically proven CRC, who
received surgical treatment with curative intent from a
single-institution, Kaohsiung Medical University Hos-
pital, from January 2002 to December 2008. The present
study was approved by the Institutional Review Board of
the Kaohsiung Medical University Hospital. Patients’
clinical outcomes and survival statuses were regularly
followed up. Available variables included: age of onset,
sex, tumor location, histological type, TNM classification
defined according to the criteria of the American Joint
Commission on Cancer (AJCC) [26], vascular invasion,perineural invasion, preoperative serum level of albumin,
preoperative and postoperative serum level of CEA,
comorbidity of cardiac disease, pulmonary disease, and
renal disease, chemotherapy, and body mass index
(BMI). The diagnoses of DM were made according to
the chart record of a history of DM or taking medicines
for DM. Preoperative serum levels of albumin and CEA
were checked within one week before the operation, and
postoperative serum levels of CEA were checked at least
four weeks after. The cut-off values of serum albumin
and CEA were set at 3.5 gm/dl and 5 ng/ml, respectively.
The diagnosis of diabetes mellitus was made according
to the records of the charts. The existences of comorbid-
ity were according to the chart record of International
Classification of Diseases (ICD, 9th version), that are
ICD codes 390 to 398, 410 to 414, and 420 to 429 for
cardiac disease, 490 to 496 for pulmonary disease, 584 to
588 for renal disease.
All patients were followed up until their deaths, or
untill December 2010. The median follow-up time was
32 months (range: 1 to 96 months). Cancer-specific sur-
vival was defined as the time elapsed between primary
surgery and death from CRC. Overall survival was
defined as the time elapsed between primary surgery
and death from any cause.
Statistical analysis
All data were statistically analyzed using the Statistical
Package for the Social Sciences, version 17.0 (SPSS Inc.,
Chicago, IL, USA). For the univariate statistical analysis,
a Chi-square test was used where applicable. A Cox pro-
portional hazards model with forward stepwise variable
selection was used for multivariate testing of those fac-
tors found to be significant by univariate analysis (the in-
clusion factors were those with P-value less than 0.05 by
univariate analysis). Overall and cancer-specific survival
rates (OS and CSS) were calculated by the Kaplan-Meier
method, and the differences in survival rates were ana-
lyzed by the log-rank test. A P-value less than 0.05 was
considered to be statistically significant.
Results
Characteristics of colorectal cancer patients
The clinical and pathologic data regarding 1,197 CRC
patients are summarized in Table 1. There were 283
(23.6%) patients diagnosed with diabetes mellitus.
Patients in the DM group were significantly older than
patients in the non-diabetes group (67.63 ± 10.55 vs
63.11 ± 13.45, P <0.001). Low preoperative serum albu-
min level was prominently encountered in patients
with DM when compared to patients without DM
(44.9% vs 38.2%, P =0.018). Higher preoperative and
postoperative serum CEA were more frequently
observed in patients with DM when compared to
Table 1 Baseline characteristics of 1197 colorectal cancer patients by diabetes mellitus and non- Ddiabetes mellitus
status
Characteristic Diabetes (%) Non-diabetes (%) P value
N= 283 (23.6%) N= 914 (76.4%)
Age (mean ± SD) 67.63 ± 10.55 63.11 ± 13.45 < 0.001
Gender
Male/Female 157 (55.5)/126 (45) 516 (56.5)/398 (43.5) 0.772
Tumor size
≥5 cm/<5 cm 116 (41)/167 (59) 404 (44.2)/510 (55.8) 0.315
Tumor location
Colon/Rectum 199 (70.3)/84 (29.7) 629 (68.8)/285 (31.2) 0.633
Histological type
Well/Moderately/Poorly 23 (8.1)/230 (81.3)/30 (10.6) 68(7.4)/747(81.8)/99(10.8) 0.582
AJCCa Stage
I/II/III/IV 52(18.3)/109(38.5)/85(30)/37(13.2) 155(17)/316(34.6)/280(30.6)/163(17.8) 0.396
Tumor depth
T1/T2/T3/T4 20(7.0)/43(15.2)/210(74.2)/10(3.6) 61(6.7)/136(14.9)/652(71.3)/67(7.1) 0.305
Lympho Nodes metastases
N0/N1/N2 171(60.4)/76(26.9)/36(12.7) 523(57.2)/233(25.5)/158(17.3) 0.322
Vascular invasion
Yes/No 95 (33.6)/188 (66.4) 614 (67.2)/300 (32.8) 0.764
Perineurial invasion
Yes/No 102 (36)/181 (64) 344 (37.6)/570 (62.4) 0.689
Serum Albumin level
<3.5 gm/dl/≥3.5 gm/dl 127 (44.9)/156 (55.1) 349 (38.2)/565 (61.8) 0.018
Pre-op Serum CEAb level
≥5 ng/ml/<5 ng/ml 160 (56.6)/123 (43.5) 400 (43.8)/514 (56.2) < 0.001
Post-op Serum CEAb level
≥5 ng/ml/<5 ng/ml 93 (32.9)/190 (67.1) 245 (26.8)/669 (73.2) 0.024
Cardiac disease
Yes/No 173 (61.1)/110 (38.9) 311 (34)/603 (66) < 0.001
Pulmonary disease
Yes/No 4 (1.4)/279 (98.6) 12 (1.3)/902 (98.7) 0.898
Renal disease
Yes/No 15 (5.3)/268 (94.7) 40 (4.4)/874 (95.6) 0.517
Second Primary Cancer
Yes/No 27 (9.5)/256 (90.5) 55 (6)/859 (94) 0.040
Chemotherapy
Yes/No 185 (65.4)/98 (35.6) 607 (66.4)/307 (33.6) 0.756
Body Mass Index (mean ± SD) 24.36 ± 3.65 23.29 ± 3.75 < 0.001
a AJCC American Joint Commission on Cancer.
b CEA Carcinoembryonic antigen.
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vs 26.8%, P =0.024, respectively). Higher percentage of
concurrent cardiac disease was also noted in patients
with DM when compared to patients without DM
(61.1% vs 34.0%, P <0.001). Further, BMI was significantly
higher in patients with DM than patients without DM
(24.36±3.65 vs 23.29±3.75, P <0.001). However, therewere no significant differences in gender, tumor size, tumor
location, histological type, AJCC/UICC cancer stage, vascu-
lar invasion, perineural invasion, the percentages of patients
receiving chemotherapy, and comorbidity of pulmonary
disease and renal disease. In addition, DM patients had a
higher incidence of second primary malignancy than
patients without DM (9.54% vs 6.01%, P = 0.040).
Table 2 Univariate and multivariate analysis of prognostic indicators on overall survival for colorectal cancer patients
Parameters Number Univariate analysis
Hazard ratio (95% CI)
P value Multivariate analysis
Hazard ratio (95% CI)
P value
DM (yes/no) 283/914 1.02(0.81-1.27) .888 0.94(0.71-1.24) 0.642
Age (≥65/<65)years 632/565 1.33(1.09-1.62) .004 1.36(1.05-1.76) 0.021
Sex (Male/Female) 674/523 1.13(0.93-1.37) .221 1.09(0.85-1.40) 0.491
Location (Rectum/Colon) 369/828 0.89(0.65-1.00) .048 0.80(0.61-1.05) 0.114
Tumor size (≥5/<5)cm 518/679 1.47(1.21-1.78) < .001 1.12(0.87-1.44) 0.368
BMIa (<22/≥22) kg/M2 394/803 1.39(1.13-1.70) .001 1.14(0.88-1.48) 0.311
Albumin (<3.5/≥3.5)gm/dl 476/721 1.83(1.48-2.25) < .001 1.32(1.02-1.70) 0.037
Histology (PD/MD + WDb) 135/1062 1.93(1.48-2.52) < .001 1.45(1.04-2.02) 0.030
AJCCc stage (III&IV/I&II) 565/632 3.36(2.73-4.14) < .001 1.32(1.02-1.70) 0.037
Pre-op CEAd (≥5/<5) ng/ml 559/638 2.86(2.31-3.53) < .001 1.26(0.93-1.70) 0.143
Post-op CEAd (≥5/<5) ng/ml 338/859 5.30(4.30-6.54) < .001 3.61(2.80-4.64) < 0.001
Vascular invasion (yes/no) 395/802 2.79(2.28-3.41) < .001 1.58(1.22-2.05) < 0.001
Perineurial invasion (yes/no) 447/750 2.27(1.86-2.78) < .001 1.79(1.39-2.30) < 0.001
a BMI Body mass index.
b PD Poorly differentiated, MD Moderately differentiated, WD Well differentiated.
c AJCC American Joint Commission on Cancer.
d CEA Carcinoembryonic antigen.
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survival (CSS)
The results of prognostic factors on OS for CRC
patients are shown in Table 2. Using univariate analysis,
we found that older age (P = 0.004), tumor location at
rectum (P = 0.048), larger tumor size (P< 0.001), lower
BMI (P = 0.001), lower pre-operative serum albumin
level (P< 0.001), poorly differentiated histology
(P< 0.001), advanced AJCC/UICC stage (P< 0.001),
higher pre-operative and post-operative serum CEA
levels (both P< 0.001), presence of vascular invasion
(P< 0.001) and perineural invasion (P< 0.001) were
statistically significant poor prognostic factors of OS.
Using multivariate analysis, we found that older age
(P=0.021), tumor location at rectum (P=0.048), lower
pre-operative serum albumin level (P=0.037), poorly dif-
ferentiated histology (P= 0.030), advanced AJCC/UICC
stage (P=0.037), post-operative serum CEA level
(P< 0.001), presence of vascular invasion (P< 0.001) and
perineural invasion (P< 0.001) were statistically signifi-
cant poor prognostic factors of OS. However, DM was not
significantly correlated to OS by univariate analysis
(P=0.888) and multivariate analysis (P=0.642). The
results of prognostic factors on CSS for CRC patients are
shown in Table 3. Using univariate analysis, we found that
larger tumor size (P< 0.001), lower BMI (P< 0.001),
lower pre-operative serum albumin level (P< 0.001),
poorly differentiated histology (P< 0.001), advanced
AJCC/UICC stage (P< 0.001), higher pre-operative
and post-operative serum CEA levels (both P< 0.001),
presence of vascular invasion (P< 0.001) and peri-
neural invasion (P< 0.001) were statistically significant
poor prognostic factors of CSS. Using multivariateanalysis, we found that lower pre-operative serum albu-
min level (P =0.011), advanced AJCC/UICC stage
(P< 0.001), higher post-operative serum CEA level
(P< 0.001), presence of vascular invasion (P= .002) and
perineural invasion (P< 0.001) were statistically signifi-
cant poor prognostic factors of CSS. However, DM
remained not significantly correlated to CSS by univariate
analysis (P=0.888) and multivariate analysis (P=0.234).
Survival impact of DM in colorectal cancer patients
The Kaplan Meier survival analysis showed that both OS
(Figure 1A) and CSS (Figure 1B) were not significantly dif-
ferent between the two groups. Furthermore, we analyzed
the impact of DM on OS (Figure 2) and CSS (Figure 3)
according to various cancer stages. No statistical differ-
ences were found in each cancer stage in either OS or
CSS between the two groups. Furthermore, we analyzed
the impact of DM on OS and CSS according to tumor lo-
cation. OS measures were not significantly different be-
tween either colon or rectal cancer patients with and
without DM (Additional file 1: Figure S1). Likewise, CSS
measures were also not significantly different between ei-
ther colon or rectal cancer patients with and without DM
(Additional file 2: Figure S2).
Discussion
In the present study, we found a considerably higher
prevalence of DM in Taiwan CRC patients (23.6%) than
previous reports. However, there was no significant sur-
vival impact of DM on survival (OS and CSS) in these
patients. DM has been reported previously to be asso-
ciated with increased risk of CRC [12-19]. In our 1197
Table 3 Univariate and multivariate analysis of prognostic indicators on cancer-specific survival for colorectal cancer
patients
Parameters Number Univariate analysis
Hazard ratio (95% CI)
P value Multivariate analysis
Hazard ratio (95% CI)
P value
DM (yes/no) 283/912 0.91(0.72-1.17) .463 0.83(0.61-1.23) 0.234
Age (≥65/<65)years 632/565 1.19(0.97-1.46) .092 1.27(0.97-1.67) 0.083
Sex (Male/Female) 674/523 1.08(0.88-1.32) .467 1.05(0.81-1.37) 0.692
Location (Rectum/Colon) 369/828 0.81(0.64-1.00) .058 0.82(0.62-1.09) 0.176
Tumor size (≥5/<5)cm 518/679 1.42(1.15-1.74) < .001 1.13(0.86-1.47) 0.384
BMIa (<22/≥22) kg/M2 394/803 1.43(1.16-1.77) < .001 1.16(0.88-1.51) 0.301
Albumin (<3.5/≥3.5)gm/dl 476/721 1.79(1.44-2.23) < .001 1.40(1.08-1.82) 0.011
Histology (PD/MD + WDb) 135/1062 1.89(1.42-2.52) < .001 1.35(.094-1.94) 0.124
AJCCc stage (III&IV/I&II) 565/632 3.95(3.15-4.96) < .001 2.22(1.65-2.99) < 0.001
Pre-op CEAd (≥5/<5) ng/ml 559/638 2.98(2.38-3.73) < .001 1.25(0.91-1.73) 0.225
Post-op CEAd (≥5/<5) ng/ml 338/859 5.47(4.39-6.81) < .001 3.71(2.84-4.83) < 0.001
Vascular invasion (yes/no) 395/802 2.97(2.40-3.67) < .001 1.54(1.18-2.01) 0.002
Perineurial invasion (yes/no) 447/750 2.51(2.03-3.10) < .001 1.82(1.40-2.37) < 0.001
a BMI Body mass index.
b PD Poorly differentiated, MD Moderately differentiated, WD Well differentiated.
c AJCC American Joint Commission on Cancer.
d CEA Carcinoembryonic antigen.
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Barone et al. conducted two meta-analysis systematic
reviews and found 8 to 18% of CRC patients with preex-
isting DM [27,28]. Similarly, Stein et al. reported 2 to
18% of comorbidity of CRC and DM in a meta-analysis
systematic review [29]. The prevalence of DM in CRC
patients varied between 2.8% and 14% in recent other
studies from various countries [22,25,30-33]. Our recent
study and another study from Huang et al. [24] showed
that the coexistence of DM and CRC in Taiwanese
patients were relatively higher (17% and 23.6%, respect-
ively) than data from other studies.
In the current study, the patients in the DM group were
significantly older than the patients in the non-diabetesFigure 1 Overall survival (A) and cancer-specific survival (B) for CRC pgroup. Consistent with our study, two recent studies also
indicated that patients with diabetes were significantly older
than those without diabetes, and no significant difference
was found with regard to gender, tumor stage, or histo-
logical grade [24,25]. Chen et al. noted that diabetic patients
were on average 5.3 years older than non-diabetic patients,
but it was not statistically significant [33], whereas Chiao
et al. reported that age was not significantly different be-
tween those with diabetes compared to non-diabetics [34].
They noted that patients with diabetes had significantly
higher BMI. Regarding prognostic factors, age was signifi-
cantly correlated to OS, but not significantly correlated to
CSS. Our study team also demonstrated previously that older
age may be associated with cardiovascular diseases or otheratients by diabetes status.
Figure 2 Overall survival for CRC patients by stage status between diabetes and non-diabetes status.
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Society of Anesthesiologists (ASA) classifications; hence,
older age is associated with poor OS, but not CSS in CRC
patients [35]. Serum albumin level, histology, AJCC/UICC
stage, post-operative serum CEA levels, vascular invasion,
and perineural invasion were previously reported as prognos-
tic factors of CRC [35-40], and we also identified these fac-
tors were significantly correlated to OS and CSS in the
current investigation.
In fact, our findings suggested no survival impact of pre-
existing DM on OS, and the overall mortality rates between
patients with DM and those without DM were similar
(35.3% vs 35.1%). Our findings were consistent with other
studies [33,34,41,42]. However, there are controversies
about survival impact of preexisting DM on OS. It was
reported that patients with DM, compared with patients
without DM, experienced a significantly worse five-year OS
[22,24,25,29,31,43]. Again, our findings also suggested no
survival impact of preexisting DM on CSS, in consistency
with other studies [15,31]. In contrast, there were studiesreporting that diabetes confers increased risk for long-term
cancer-specific mortality [29,43]. There are still controver-
sies about survival impact of preexisting DM on CSS.
Coughlin et al. suggested that diabetes was significantly
associated with fatal colon cancer in men and women; how-
ever, diabetes was not significantly associated with fatal rec-
tal cancer in men and women [23]. Regarding CSS
according to tumor location, CSS was not significantly dif-
ferent between colon cancer patients with DM and those
without DM, and also not significantly different between
rectal cancer patients with DM and those without DM in
our studies. Huang et al. identified DM as a poor prognos-
tic factor for CSS, particularly in patients with stage II colon
cancer [24].
The decision-making of clinical treatment for CRC will
be probably influenced by the preexisting DM. van de Poll-
Franse et al. noted that colon cancer and rectal cancer
patients with diabetes were more likely to receive surgery
and less likely to receive chemotherapy. Meanwhile, rectal
cancer patients with diabetes were less likely to receive
Figure 3 Cancer-specific survival for CRC patients by stage status between diabetes and non-diabetes status.
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be due to concurrent cardiovascular diseases or worse func-
tional status. In the present study and another study [25],
higher percentages of concurrence of cardiac disease were
noted in patient with DM when compared to patients with-
out DM. Chiao et al. also reported patients with diabetes
were less likely to receive chemotherapy and radiotherapy
compared to those without diabetes [34]. However, some
studies reported no significant difference for cancer
treatment (chemotherapy and surgery) [24,25,30,33].
Huang et al. pointed out that there was a 5.2% absolute
difference in the proportion of complete adjuvant in
stage II patients; despite this difference, statistical sig-
nificance was not achieved [24]. In the present study,
the percentages of patients receiving chemotherapy
were not significantly different in the two groups. Con-
sequently, the similar survival outcomes (OS and CSS)
may partially result from the similar treatment modal-
ities between the two groups.There are some limitations of the present study. First, the
present study is a single-institution retrospective study. The
diagnosis of DM was made according to the records of the
charts. Therefore, some patients who had DM may be diag-
nosed to be non-DM. Second, the severities of comobidities
were not assessed. The presence of a comorbidity occurs in
only a relatively small group of patients, and is also the
limitation of the current study for the further stratification
of severities of comorbidity between DN and non-DM
patients. Third, the types of treatment, length of treatment,
and, treatment-related toxicities were also not assessed.
Consequently, the present study is not necessarily represen-
tative of Taiwan as a whole. Finally, as in the majority of the
literature, we did not differentiate the types of DM. The
mean age of the patients with diabetes was 67 years; the
majority of patients with diabetes were supposed to have
type 2 DM. In addition, the unavailability of serum level of
HbA1c is also a limitation of the present study. Siddiqui
et al. reported that elevated HbA1c is an independent
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CRC [42]. In patients with type 2 DM who have CRC,
poor glycemic control is associated with a clinically ag-
gressive course for the cancer. The mean values of
HbA1c were significantly improved within the controlled
range in the year after CRC diagnosis [34]; hence, the
quality of DM care before and after CRC diagnosis posi-
tively impacted survival among diabetics. Because not all
the HbA1c data are available, we cannot demonstrate
whether no significant survival impact of DM on survival
is due to good quality of DM care. However, because
the accessibility of DM care, including clinic visits and
medicine administrations, is very convenient and the
medical fee is largely covered by the Taiwan National
Health Bureau Program, the qualities of DM care are
supposed to be favorable.Conclusions
Our findings suggest that a prominently high prevalence
of DM (23.6%) is a crucial issue of public health in our
CRC patients. There is no significant survival impact of
DM on survival (OS and CSS) in patients with newly
diagnosed CRC; therefore, CRC patients with DM
should be treated with the same modalities (including
surgery and chemotherapy) as those without DM. More
large-scaled multiple center studies are needed to ascer-
tain the impact of DM on the clinical outcome of CRC
patients.Additional filesAdditional file 1: Figure S1. Overall survival for CRC patients by tumor
location between diabetes and non-diabetes status.
Additional file 2: Figure S2. Cancer-specific survival for CRC patients
by tumor location between diabetes and non-diabetes status.Abbreviations
AJCC: American Joint Commission on Cancer; BMI: Body mass index;
CEA: Carcinoembryonic antigen; CRC: Colorectal cancer; CSS: Cancer-specific
survival; DM: Diabetes mellitus; MD: Moderately differentiated; OS: Overall
survival; PD: Poorly differentiated; WD: Well differentiated.
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